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Abstract
Human cancer genomes are highly complex, making it challenging to identify specific drivers of cancer growth,
progression, and tumor maintenance. To bypass this obstacle, we have applied array comparative genomic hybridization
(array CGH) to zebrafish embryonal rhabdomyosaroma (ERMS) and utilized cross-species comparison to rapidly identify
genomic copy number aberrations and novel candidate oncogenes in human disease. Zebrafish ERMS contain small, focal
regions of low-copy amplification. These same regions were commonly amplified in human disease. For example, 16 of 19
chromosomal gains identified in zebrafish ERMS also exhibited focal, low-copy gains in human disease. Genes found in
amplified genomic regions were assessed for functional roles in promoting continued tumor growth in human and
zebrafish ERMS – identifying critical genes associated with tumor maintenance. Knockdown studies identified important
roles for Cyclin D2 (CCND2), Homeobox Protein C6 (HOXC6) and PlexinA1 (PLXNA1) in human ERMS cell proliferation.
PLXNA1 knockdown also enhanced differentiation, reduced migration, and altered anchorage-independent growth. By
contrast, chemical inhibition of vascular endothelial growth factor (VEGF) signaling reduced angiogenesis and tumor size
in ERMS-bearing zebrafish. Importantly, VEGFA expression correlated with poor clinical outcome in patients with ERMS,
implicating inhibitors of the VEGF pathway as a promising therapy for improving patient survival. Our results demonstrate
the utility of array CGH and cross-species comparisons to identify candidate oncogenes essential for the pathogenesis of
human cancer.
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Introduction
Rhabdomyosaroma (RMS) is the most common soft tissue
sarcoma of childhood [1] and falls into two major histopathologic
subtypes in children - embryonal and alveolar. Embryonal
rhabdomyosaroma (ERMS) accounts for approximately 60% of
childhood cases and is frequently associated with RAS pathway
activation [2–5]. Treatment for either RMS subtype requires
surgical resection, chemotherapy, and radiation with overall poor
prognosis for patients with high-risk features, metastasis, or relapse
disease. Thus, there is great interest in elucidating key molecular
pathways and genetic factors that are involved in continued RMS
growth and tumor maintenance. Cytogenetic studies, including
array Comparative Genomic Hybridiation (array CGH), identify
frequent but inconsistent gains and losses of whole or partial
chromosome arms and rare focal high-level amplifications in both
human ERMS and ARMS [5–9], largely precluding the identi-
fication of specific drivers of cancer in this disease. Moreover,
array CGH and cross-species comparisons between mouse and
human RMS have largely failed to identify functionally important
genes contained within common copy number alterations (CNAs).
In one report, RMS that arose in Ptch1+/2 Blmtm3Brd/tm3Brd (a
hypomorphic Blm allele) mice exhibited a gain of chromosome 10
in 80% of cases [10], but the oncogenes associated with this
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chromosomal gain remain undefined due to the large number of
candidate genes found within this region. Moreover, extension of
these findings to human RMS has not been reported. Rubin et al.
recently showed that greater than 30% of ERMS arising in mice
that harbor p53 homozygous deletion and/or Ptch1 heterozygous
deletion lack a defined molecular signature or genetic lesion,
suggesting undiscovered pathways likely contribute to ERMS
transformation, growth, and tumor maintenance [11]. To date,
there remains a need for novel gene discovery methods to identify
genes and pathways essential for tumor growth, progression, and
maintenance in human cancer – including ERMS.
Zebrafish cancer shares molecular and pathological similarities
to human disease [4,12–16]. For example, Lam et al. (2006) was
the first to use comparative analysis of microarray data from
zebrafish and human liver tumors to demonstrate a conserved
molecular profile during tumor progression [13]. Building on this
work, microarray gene expression studies of zebrafish ERMS and
cross-species comparison to human disease identified RAS
pathway activation as a common initiating event in zebrafish
and human ERMS. Activating RAS mutations have also been
identified in numerous studies of human ERMS [2–5,17]. Most
recently, Paulson et al reported that 11 of 26 (42%) human ERMS
samples harbored activating RAS mutations along with acquisition
of additional CNAs as detected array CGH [5], suggesting that
additional genetic lesions are likely required to drive oncogenic
transformation to ERMS. Not surprisingly, zebrafish cancers also
exhibit recurrent chromosomal gains and losses similar to those
found in human cancer. For example, transgenic models of
zebrafish melanoma, T-cell acute lymphoblastic leukemia (T-
ALL), and ERMS contain genomic imbalances including high-
level gains and losses [18]. However, specific driver events could
not be identified in these studies due to the low resolution of this
platform. Using high-resolution array CGH, Zhang et al (2010)
demonstrated the aneuploid nature of zebrafish malignant nerve
sheath tumors (MPNST), a feature that also characterizes the
human disease, and identified a subset of genes that are
co-amplified as high-copy gains in human MPNST [19]. High-
resolution array CGH has also been applied to zebrafish T-ALL
and identified a subset of genes contained within CNAs that were
also amplified or deleted in human disease [20]. These latter two
studies have demonstrated the utility of array CGH technology in
detecting copy number aberrations and candidate driver genes in
zebrafish tumor models, yet functional relevance of identified
genes in human disease has not been reported nor have these
genes been assessed for roles in regulating tumor maintenance –
providing novel targets for therapy in established tumors.
Capitalizing on a zebrafish model of kRASG12D-induced ERMS
that shares common histopathological, genetic, and molecular
characteristics of human ERMS [4,21,22], we have utilized high-
resolution array CGH to identify novel CNAs in ERMS.
Remarkably, our array CGH analysis revealed focal CNAs that
span short genomic regions and contain only 1–3 genes. To
validate the functional significance of amplified genes in human
ERMS, we prioritized six genes for initial characterization in
human ERMS cell lines. Of these six genes, gene knockdown of
Cyclin D2 (CCND2), Homeobox C6 (HOXC6), PlexinA1 (PLXNA1)
inhibited proliferation of human ERMS. PLXNA1 also exhibited
important roles in blocking ERMS cells in early stages of muscle
differentiation, enhancing migration, and altering anchorage-
independent growth. CCND2, HOXC6, PLXNA1, and Vascular
Endothelial Growth Factor A (VEGFA) were also highly expressed
in a large fraction of human primary RMS, supporting prominent
roles for these genes in rhabdomyosarcoma. Chemical inhibition
of VEGF signaling reduced tumor growth in vivo with an associated
decrease in angiogenesis, implicating VEGF inhibitors as prom-
ising therapeutic agents for ERMS. Taking advantage of tractable
features of zebrafish cancer genomes such as smaller CNA
intervals and regions of conserved homology with human disease,
our study demonstrates the effective use of array CGH to identify
oncogenes required for continued tumor growth in human
rhabdomyosaroma, providing novel therapeutic targets for the
treatment of ERMS.
Results
Zebrafish array CGH identifies novel and conserved CNAs
in human ERMS
Array CGH was performed on genomic DNA isolated from
twenty kRASG12D-induced zebrafish ERMS and compared to
adjacent normal tissue. Array CGH revealed a complex CNA
pattern with relative gains being observed more frequently than
losses. For example, we identified 190 regions of amplification and
35 deletions recurrent in$3 zebrafish tumors analyzed (Table S1).
Remarkably, only 2 of 20 zebrafish samples exhibit evidence of
aneuploidy, contrasting starkly with human ERMS where nearly
all human RMS harbored regions of extensive aneuploidy [5].
While 10 zebrafish ERMS showed evidence for CNAs in coding
regions of the genome, only 3 exhibited a high frequency of
multiple gains (Table 1 and S1). In total, we identified 19 gains
and 2 losses in gene-containing amplicons that were recurrent in at
least three zebrafish ERMS samples. Candidate genes in these
regions were predominantly amplified as low-level gains, which
averaged 1–3 genes and spanned only 48+/227 kb (+/2 SD,
Table 1; Fig. 1A). Copy number alterations were validated by
qPCR of genomic DNA (Fig. S1).
To assess whether CNAs identified in zebrafish ERMS were
conserved in human disease, zebrafish array CGH data was
compared to the high-resolution array CGH data from 26 human
ERMS samples [5]. Of the 26 samples, 11 carried activating RAS
mutations as assessed by Sanger sequencing analysis [5]. The two
Author Summary
Cancer is a complex genetic disease that is often
associated with regional gains and losses of genomic
DNA segments. These changes result in aberrant gene
expression and drive continued tumor growth. Because
amplified and deleted DNA segments tend to span large
regions of chromosomes, it has been challenging to
identify the genes that are required for continued tumor
growth and progression. Array comparative genomic
hybridization (array CGH) is an effective technology in
identifying abnormal copy number variations in cancer
genomes. In this study, array CGH was used in a zebrafish
model of embryonal rhabdomyosarcoma - a pediatric
muscle tumor. Our work shows that the zebrafish cancer
genome contains a small number of recurrent DNA copy
number changes, which are also commonly amplified in
the human disease. Moreover, these chromosomal regions
are small, facilitating rapid identification of candidate
oncogenes. A subset of genes identified in zebrafish array
CGH was prioritized for functional characterization in
human ERMS, identifying evolutionarily conserved path-
ways that regulate proliferation, migration, differentiation,
and neovascularization. Our results demonstrate the broad
utility of cross-species array CGH comparisons of human
and zebrafish cancer and provide a much needed
discovery platform for identifying critical cancer-causing
genes in a wide range of malignancies.
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regions of chromosomal loss in zebrafish ERMS contained
zebrafish-specific genes that failed to have human homologues
(Table 1). By contrast, genes contained within the 19 CNA gains
mapped to 21 distinct homologous genomic regions in human.
Utilizing the same statistical algorithms and threshold settings as
outlined by Paulson et al [5], we discovered that 18 of 21
homologous regions were also amplified as low-copy gains in
human ERMS samples (Table 1). Like zebrafish ERMS, these
CNAs were focal, low-copy gains spanning 328 kB+/2278 kB
and contained 7.3 genes on average (Table 1 and S1).
To demonstrate the efficacy of our array CGH approach to
identify evolutionarily conserved oncogenes essential for driving
tumor progression and maintenance, we prioritized CNAs that
contained genes and were amplified in both zebrafish and human
ERMS. In total, six candidate genes were prioritized for further
study in human ERMS based on the following criteria. 1)
Figure 1. Array CGH reveals cancer-specific chromosomal abnormalities in zebrafish ERMS. (A) Summary of common gene-containing
CNA gains (green) and losses (red) in 20 animals examined. Only recurrent CNAs found in $3 samples are shown. The height of each bar correlates
with the frequency of each aberration. Detailed view of regional gains for vegfa on chromosome 4 (B), ccnd2a on chromosome 25 (C), hoxc6a on
chromosome 23 (D), and plxna1 on chromosome 6 (E). Y-axis denotes log2 ratio of the probes and X-axis denotes genomic coordinates.
doi:10.1371/journal.pgen.1003727.g001
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Candidate oncogenes were differentially expressed in human
ERMS compared to ARMS and/or normal muscle as assessed by
microarray gene expression studies. 2) Genes that have known
oncogenic activity in other cancer types, but yet ascribed
functional roles in ERMS, were prioritized for additional study
to serve as ‘‘proof of concept’’ genes in our cross-species
comparative study. 3) A subset of genes was selected which have
unknown function in ERMS and represent potential novel
oncogenes. 4) Amplified CNA regions that harbored a single
human homologue were also prioritized. Based on these criteria,
CCND2, HOXC6, PLXNA1, VEGF, BRAF and LIMK1 were selected
for further study (Table 1). CCND2, PLXNA1, VEGFA, and LIMK1
were the single genes contained within the amplified CNA
intervals in human disease. BRAF was the only gene in the
interval that was overexpressed in human ERMS, whereas CRY1
and TNNT1 identified within the same amplified interval were not
differentially expressed when comparing human ERMS to normal
muscle (Fig. S2). HOXC6 has been reported to be highly expressed
in human ERMS compared with ARMS [23], suggesting an
possible role in modulating tumor growth. While CCND2, a cell
cycle regulator, VEGFA, an essential regulator of angiogenesis in a
variety of cancer types and BRAF, an oncogene in a variety of
cancers, most likely serve as our ‘‘proof of concept’’ genes for
demonstrating functional significance in human ERMS. LIMK1,
HOXC6 and PLXNA1 represent potential novel candidate genes for
driving tumor growth of ERMS.
A subset of amplified genes play essential roles in
regulating ERMS proliferation
The six candidate genes were first assessed for anti-proliferative
effects in human RD and SMS-CTR ERMS cell lines by siRNA
knockdown, establishing a role for these genes in continued tumor
growth and maintenance. Importantly, each of these human
ERMS cell lines contains mutationally-activated RAS alleles,
mimicking the zebrafish model. Effective gene knockdown was
validated by quantitative RT-PCR and/or Western analysis (Fig. 2
A and Fig. S3 B and S4 A). A quantitative VEGFA ELISA
confirmed lower levels of secreted VEGFA in the growth medium
from cells transfected with VEGFA siRNA (Fig. S3 A, p,0.05).
Gene-specific siRNA knockdown of CCND2, HOXC6 and PLXNA1
resulted in reduced cell viability as assessed by a luminescent cell
viability assay in both cell lines (Fig. 2 B and S4 B–H). By contrast,
knockdown of BRAF, LIMK1, or VEGFA failed to alter viability
and/or growth in both cell lines (Fig. 2 B and 2 C and data not
shown). Following validation of growth effects using two additional
siRNAs for CCND2, HOXC6 and PLXNA1 in RD and SMS-CTR
cell lines (Fig. 2 C and S4 B–H), these genes were prioritized for
additional functional studies. For example, knockdown of CCND2,
HOXC6 and PLXNA1 resulted in reduced EDU incorporation
when compared to cells transfected with control siRNA in both
RD and SMS-CTR cell lines, suggesting that inhibition of cell
growth resulted from a block in proliferation (Fig. 2 D). Apoptosis
was not altered by gene knock down as assessed by Annexin V
staining (Fig. S5). In total, our data uncovered important roles for
CCND2, HOXC6 and PLXNA1 in regulating ERMS prolifera-
tion, validating the role of several novel genes in regulating
continued tumor cell proliferation in human ERMS cells.
Knockdown of PLXNA1 results in increased terminal
differentiation and impaired anchorage-independent
growth in human ERMS
ERMS expresses myogenic factors such as MYOD and MYF5
yet it fails to complete normal myogenesis secondary to
differentiation arrest [24,25]. As a result, ERMS is composed of
heterogeneous subpopulations of proliferating tumor cells that
vary in their differentiation status. Therefore, oncogenes that are
essential for regulating proliferation of ERMS cells likely also play
a role in modulating their differentiation status. Thus, we
determined whether CCND2, HOXC6, and PLXNA1 also
played a role in blocking differentiation of ERMS. Knockdown
of PLXNA1 resulted in increased formation of multinucleated
myocytes and induction of myosin heavy chain expression in RD
cells (Fig. 3 B, p = 0.03). By contrast, siRNA knockdown of CCND2
and HOXC6 did not alter the differentiation status of human RD
cell (Fig. 3 E). To validate the phenotype of PLXNA1 knockdown,
two independent PLXNA1 shRNA knockdown stable lines were
generated and cultured under differentiation condition. Both
PLXNA1 shRNAs induced robust gene knockdown compared to
control scrambled shRNA (Fig. 3 F), resulting in increased
numbers of multinucleated-myocytes and myosin heavy chain
expression (Fig. 3 D–E, p= 0.01).
PLXNA1 also played a critical role in regulating anchorage-
independent growth in colony formation assays. Stable knockdown
of PLXNA1 resulted in impaired anchorage-independent growth
with decreased colony formation two-fold over 15 days when
compared to RD cells transduced with control shRNA (Fig. 3 G–I,
p = 0.0003). Moreover, colonies were smaller in size, likely
reflecting the prominent role of PLXNA1 in regulating cell
growth. Together, our findings indicate that PLXNA1 plays an
essential important role in regulating proliferation and differenti-
ation in transformed ERMS.
Knockdown of PLXNA1 results in impaired migration of
human ERMS cell lines
Migratory behavior of tumor cells in vitro can be a useful
predictive index of cell invasion and metastasis in vivo. Genes and
pathways that are essential for regulating the migratory behavior
of tumors cells can likely serve important functions in mediating
metastasis and therefore are potential targets for novel therapy.
Wound healing and transwell migration assays were used to assess
a role for CCND2, HOXC6, PLXNA1 and VEGFA in migration of
human RD and SMS-CTR ERMS cell lines. Knockdown of
PLXNA1 by siRNAs (smart-pool and individual siRNAs) and
shRNAs resulted in impaired migration in both RD and SMS-
CTR cells over 22 hours (p,0.02 for RD and p#0.04 SMS-CTR,
Fig. 4 G–I, Fig. S6). By contrast, knockdown of CCND2, HOXC6
and VEGFA did not affect migration of either RD or SMS-CTR
cells (p.0.25, Fig. 4 A–F, I). As an independent assessment of
ERMS cell migration, PLXNA1 stable shRNA knockdown cells
were assessed for migration in a transwell assay. Knockdown of
PLXNA1 in RD cells with two independent gene-specific shRNAs
resulted in .50% reduction in transwell migration (p= 0.03 for
shRNA-A and p= 0.0038 for shRNA-B, Fig. 4 J). Together, these
results support an additional role for PLXNA1 in regulating
migratory behavior of human ERMS cells.
Inhibition of VEGFA results in reduced angiogenesis and
tumor growth
The VEGFA pathway often exerts powerful roles in regulating
cancer-induced angiogenesis, which would have been missed in
our human cell culture assays. To assess a role for VEGFA in
modulating tumor growth in vivo, ERMS-bearing zebrafish were
treated with the VEGF receptor tyrosine kinase inhibitor,
cediranib, or DMSO vehicle for 7 days and assessed for effects
on tumor growth. Relative tumor growth as determined by the
ratio of tumor volume change between pre- and post-treatment
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was reduced by three-fold in cediranib-treated fish when
compared to those treated with vehicle (Fig. 5A–M, p=0.0017,
Student’s T-test). As VEGFA is known to promote angiogenesis
during tumor progression in a variety of cancers, we next assessed
whether inhibition of VEGFA also blocked angiogenesis in ERMS
in vivo. In order to visualize angiogenesis in established tumors,
ERMS co-expressing rag2-KRASG12D and rag2-dsRED were
transplanted into irradiated fli1-GFP fish that exhibit vessel-
specific GFP expression [26]. Fish with engrafted ERMS were
treated with either cediranib or DMSO vehicle for 7 days. Animals
were assessed for differences in both overall tumor growth and
microvessel density as determined by cryosections of tumors.
ERMS-affected animals treated with cediranib showed a signifi-
cant reduction in tumor growth with an accompanied two-fold
reduction in tumor microvessel density when compared to those
treated with vehicle control (N= 5 for each group, p = 0.006, Fig. 5
N–P). Cediranib-treated ERMS did not exhibit a difference in
proliferation when compared to vehicle control-treated tumors
(Fig. 5 Q–S), consistent with our results for VEGFA gene
knockdown in human ERMS cell lines. Together, these data
suggest that activation of the VEGF pathway promotes ERMS
tumor progression through enhanced angiogenesis.
CCND2, HOXC6, PLXNA1 and VEGFA are commonly
expressed in human rhabdomyosaroma
Having established roles for CCND2, HOXC6, PLXNA1 and
VEGFA in ERMS growth, we next wanted to assess the extent to
which these proteins are expressed in human primary RMS.
Immunohistochemistry was performed using antibodies to
CCND2, HOXC6, PLXNA1 and VEGFA in primary human
tumors and fetal muscle (Supplemental Table S2). In all, 8
pediatric and 11 adult ERMS and 3 pediatric and 4 adult alveolar
RMS (ARMS) were analyzed. Remarkably, CCND2, HOXC6,
PLXNA1 and VEGFA protein expression were detected in a
majority of RMS samples while antibody staining for each was
largely negative in fetal muscle (Fig. 6). Specifically, HOXC6
protein expression was detected in 14 of 19 ERMS with strong,
diffuse staining being found in 6 of the 14 cases (1 adult and 5
Figure 2. CCND2, HOXC6 and PLXNA1 exert important roles in human ERMS cell proliferation. (A) Western analysis following siRNA
knockdown in the RD cell line. The percentage of knockdown (% KD) is indicated below each lane (representative example shown for three
independent replicates). (B) Viability following siRNA gene knockdown in RD cells was assessed by cell-titer glo assay. (C) Graph summarizing the
results of the cell-titer glo assay. OD-fold change over 3 days in RD cell line from knockdown by smart-pool and two individual gene-specific siRNAs is
indicated. (D) Summary of EDU proliferation analysis from RD and SMS-CTR ERMS cell lines,. (Asterisks denote significant differences between siRNA
knockdown compared to control siRNA (p,0.05). Each error bar in B, C, and D denotes standard deviation of 3 independent experiments.
doi:10.1371/journal.pgen.1003727.g002
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pediatric). In contrast, only 2 of 7 ARMS showed weak, positive
staining for HOXC6, consistent with lower-level gene transcript
levels being detected in pediatric ARMS compared to ERMS
(Supplemental Fig. S7). CCND2, PLXNA and VEGFA were
expressed at comparable frequency in both subtypes of RMS.
For example, CCND2 was detected in 15 of 19 ERMS and 5 of
7 ARMS, while PLXNA1 expression was found in 17 of 19
ERMS and 6 of 7 ARMS. VEGFA antibody staining was
detected in the tumor cells and the vasculature in 10 of 19
ERMS (strong staining in 1 adult and 1 pediatric case), while 6
of 7 ARMS exhibited weak staining in all cases analyzed.
Additional immunohistochemical analysis of a tissue microarray
from Children’s Oncology Group revealed positive VEGF
expression in 31 of 38 ERMS and 3 of 6 ARMS (Table S3).
Of the 38 cases of ERMS, 29 cases showed strong and diffuse
staining. Our analysis suggests that despite these oncogenes
being infrequently amplified in human disease, their protein
expression levels are elevated in a majority of human ERMS.
These data imply important roles for these genes in regulating
tumor growth in a large fraction of human ERMS and
suggesting additional, as of yet undiscovered mechanisms that
regulate expression of these genes.
High VEGFA expression correlates with clinical outcome
To assess whether dysregulated expression of CCND2, HOXC6,
PLXNA1 and VEGFA correlates with clinical outcome, Kaplan
Meier analyses were completed using microarray gene expression
data from primary ERMS and ARMS [23]. Samples were
stratified based on high and low median expression for each gene
and each assessed as an independent predictor of survival. Based
on this analysis, differential expression of CCND2 and PLXNA1 did
not correlate with overall survival outcome in either ERMS or
ARMS (Fig. S8). HOXC6 was differentially upregulated in ERMS
compared to ARMS (Fig. S7); thus, high expression of HOXC6
correlated with better overall survival (Fig. 7 A), a finding
consistent with previous studies demonstrating better clinical
outcome for ERMS patients compared to those with ARMS [27].
Finally, samples with high mRNA expression of VEGFA correlated
with low overall clinical survival in the ERMS cohort but did not
predict survival outcome in ARMS (Fig. 7 B). In addition, VEGFA
expression did not correlate with clinical stage, indicating that it is
likely an independent prognostic indicator (Fig. S9). These data
implicate important roles of VEGFA in promoting ERMS tumor
progression and identify VEGFA as a biomarker with likely use in
stratifying ERMS patients into high and low-risk groups.
Figure 3. Knockdown of PLXNA1 induced differentiation and impaired anchorage-independent growth of human ERMS cells. RD
cells stained with myosin heavy chain (MF20) and DAPI following culture under differentiation conditions for 72 hrs. (A) Control siRNA. (B) PLXNA1
smart-pool siRNA. (C) Control scrambled shRNA. (D) PLXNA1 shRNA-1. DAPI, blue; MF20-positive cell, green. (E) Quantification of MF-20
immunofluorescence in siRNA and shRNA-knockdown RD cells. Asterisk indicates significant differences between gene knock- down and control cells
(p,0.05). Error bars denote standard deviation. (F) Western analysis of PLXNA1 shRNA stable knockdown; sc, scrambled control shRNA; 1, PLXNA1
shRNA-1; 2, PLXNA1 shRNA-2. A soft agar colony formation assay to assess PLXNA1 knockdown effects on anchorage-independent growth (G–I). (G)
Control scrambled shRNA. (H) PLXNA1 shRNA. (I) Quantification of colony formation assay results. Error bar indicates standard deviation from triplicate
experiments.
doi:10.1371/journal.pgen.1003727.g003
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Discussion
Prior cytogenetic and array CGH studies in human ERMS
demonstrate inconsistent and non-specific partial to whole
chromosomal aneuploidy across different primary tumors
making it difficult to identify critical genes essential for driving
tumor growth. Utilizing a zebrafish model of RAS-induced
ERMS that mimics the human disease [4,21] and subsequent
array CGH analyses of genomic DNA from tumor vs. matched
normal, we were able to rapidly identify candidate gene-
containing regions that likely contribute to ERMS pathogenesis.
The 19 CNA gains that were recurrently amplified in zebrafish
ERMS mapped to 21 homologous regions within the human
genome. Remarkably, 18 of these regions also demonstrated
low-level genomic amplification in human ERMS. To validate
that candidate genes contained within these intervals exert
important roles in continued tumor growth and maintenance,
we characterized the function of six amplified genes in human
ERMS cell lines and conclusively demonstrated functional
significance of CCND2, HOXC6, PLXNA1 in proliferation of
human ERMS. PLXNA1 also has important roles in regulation
differentiation and migration of ERMS cells. As the in vitro
analyses performed in this study would not be able to assess
other aspects of tumorigenesis such as neovascularization and
tumor initiation, we utilized the zebrafish in vivo model to
demonstrate the important role of VEGF-A pathway in
mediating angiogenesis during tumor growth. In total, our
work identified roles for 4 of 6 candidate genes identified in our
cross-species array CGH studies for eliciting important roles in
human ERMS. Importantly, this strategy is not limited to
zebrafish ERMS, and will likely provide powerful new methods
to identify novel tumor-suppressor and oncogenes in a wide
range of zebrafish and human tumors.
Data from our array CGH study and previous studies of
zebrafish cancer revealed low-level CNA gains as a frequent
DNA alteration in cancer, yet this class of mutation has not
commonly been studied due to the difficulty in identifying
relevant and meaningful genes in these regions. Importantly,
zebrafish allows for the easy identification of low-level gene
amplifications. In total, our data is consistent with a model
where zebrafish tumor cells undergo acquisition of low-
amplitude gains, likely represented as single copy gains within
CNA regions. For example, we have also observed that clonal-
populations of purified T-ALL cells (90% enriched for blasts)
also contain low-amplitude gains [Blackburn et al., unpub-
lished]. Moreover, Rudner et al. (2011) recently showed that a
majority of amplified, gene-containing CNAs found in zebrafish
T-ALL were also amplified in human disease [20]. Upon re-
analysis of this data, we find that 72% of the reported amplified
regions were detected as low-level gains in zebrafish T-ALL,
yet were not reported as such. Zhang et al. identified large
regions of aneuploidy and high-level CNA gains in zebrafish
malignant peripheral nerve sheath tumors when assessed by
array CGH, but also identified numerous regions of low-level
CNA gains, which were dismissed as potential causative lesions
in cancer. Thus, despite these previous two reports observing
low-level CNA gains in zebrafish malignancy, neither reported
the functional importance of this class of genes to promote
tumor progression and maintenance in zebrafish or human
disease. Although it is formally possible that low level gains
detected in zebrafish ERMS represent high-copy gains masked
by a high degree of tumor cell heterogeneity and/or
contamination of normal DNA from non-transformed blood,
fibroblasts and stroma, our data strongly argue that low-copy
Figure 4. Knockdown of PLXNA1 impairs migration of human
ERMS cells. Representative images of ERMS cells transfected with
gene-specific siRNAs at 0 hr (A, control siRNA; C, CCND2 siRNA; E, HOXC6
siRNA; G, PLXNA1 siRNA) and 22 hrs (B, control siRNA; D, CCND2 siRNA;
F, HOXC6 siRNA; H, PLXNA1 siRNA) following gap creation. Scale bar
indicates 100 mm. (I) Quantification of data from wound healing assay.
Each error bar indicates standard deviation across 5–6 independent
replicates. (J) A Transwell migration assay was performed in RD cells
that stably express either a control shRNA or two independent PLXNA1
shRNAs. Migration was assessed after 24 hours. Each error bar indicates
standard deviation across six fields at 2006 magnification. Asterisks
denote p,0. 05.
doi:10.1371/journal.pgen.1003727.g004
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amplification is a common attribute found in zebrafish and
human cancer.
Interestingly, even though the functional relevance of low-
level gains such as genomic duplication events have been
infrequently reported in human cancer, this type of DNA
alteration often predicts important clinical parameters such as
disease susceptibility, therapy resistance and adverse prognosis.
For example, duplication of a region on chromosome 6q27 is
detected in individuals affected with familial chordoma, a rare
bone cancer, but not among unaffected individuals within the
same family [28]. MYB tandem duplication occurs in pediatric
T-ALL and results from homologous recombination at ALU
repetitive sequences flanking the MYB locus. Elevated MYB
expression is associated with poor outcome in T-ALL [29].
Similarly, focal tandem duplication also contributes to chemo-
therapy resistance in patients with high-grade ovarian cancer
[30]. These findings indicate that low-level CNA gains
have important clinical prognostic relevance and likely play
important functional roles in human cancer. Finally, we also
found that genes within each CNA are highly expressed in a
majority of human RMS despite being infrequently amplified as
low-copy CNAs, suggesting the importance of these gene
pathways in regulating a large fraction of human ERMS and
that additional mechanisms underlying the dysregulation of this
class of genes in cancer is likely.
Our work has identified essential roles for four genes in
modulating ERMS growth, maintenance, migration, and neovas-
cularization. Of these genes, CCND2, HOXC6 and PLXNA1
exhibited important roles in regulating proliferation in human
ERMS cell lines. PLXNA1 also had additional roles in arresting
ERMS cells in early stages of muscle differentiation, in enhancing
tumor cell migration, and in altering anchorage-independent
growth. Despite the fact that these genes and/or related family
members have been ascribed functions in other cancer types, their
contributions to the pathogenesis of ERMS have not been
previously characterized. For example, HOXC6, a homeobox
Figure 5. Chemical inhibition of VEGF signaling by cediranib reduces ERMS growth in vivo. Syngeneic CG1 fish were transplanted with
ERMS cells that co-expressed rag2-KRASG12D and rag2-dsRED. Fish with engrafted tumors were treated with DMSO vehicle (A–F) or 100 nM of
cediranib for 7 days (G–L). Pre-treatment (A–C and G–I) and post-treatment images (D–F and J–L) of representative fish. Bright field (A,D,G,J), dsRED
fluorescence (B,E,H,K) and merged image planes (C,F,I,L). Scale bar is 3 mm. (M) Quantification of relative volume change for individual animals. (N–O)
fli1-GFP transgenic zebrafish were transplanted with dsRED-labeled ERMS and treated with DMSO (N) and cediranib (O). Scale bar equals 50 mm. (P)
Microvessel density quantification. Asterisk indicates statistically significant difference between DMSO and cediranib-treated groups based on
student t-test. Each error bar indicates standard deviation from 3 fields of microvessels for each animal. EDU incorporation analysis in DMSO (Q) or
cediranib (R) treated fish. Scale bar is 50 mm. (S) Quantification of EDU analysis across each cohort of animals. Each error bar indicates standard
deviation of percent EDU+ cells found within 3 fields for each animal.
doi:10.1371/journal.pgen.1003727.g005
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transcription factor, regulates the expression of genes including
BMP7, FGFR2, IGFP3 and PDGFRA to influence oncogenic
activities in prostate cancer [31]. HOXC6 is highly expressed in
ERMS but not ARMS [23], suggesting a specific and independent
role in regulating growth in the human ERMS subtype. A role for
HOXC6 in regulating continued RMS growth had not been
reported until this study. CCND2 belongs to the D-type G1 cyclins
(D1, D2 and D3). While cyclin D1 is frequently dysregulated in
cancer and is a marker for disease progression [32], the
involvement of cyclin D2 in cancer is not as well characterized.
CCND2 is amplified in 2% of gliomas and in zebrafish and human
MPNSTs [19,33]. Finally, PLXNA1 belongs to a highly conserved
family of transmembrane receptors that bind semaphorins and
have been shown to mediate neuronal cell migration, guidance,
and patterning [34,35]. In humans, nine plexins group into four
subfamilies and several have been implicated as having roles in
cancer progression and growth. In particular, plexin-B1 can
function as an oncogene by promoting proliferation and survival of
B-Cell Lymphoblastic Lymphoma cells and invasion of ovarian
and breast tumor cells [36–38]. Plexin-A1, the gene identified in
our study, has been shown to activate the VEGF receptor and NF-
kB to promote survival of malignant mesothelioma cells [39],
suggesting a complex interplay of PLXNA1 in cell survival and
neovascularization. Taken together, our study has demonstrated
prominent and novel roles for CCDN2, HOXC6, and PLXNA1
in modulating ERMS proliferation while PLXNA1 exerts impor-
tant additional roles in regulating differentiation and migration.
None of these genes have been previously implicated as important
modulators of ERMS growth and maintenance, suggesting that
our cross species array CGH studies will be valuable for
uncovering genetic lesions across a wide range of zebrafish and
human cancers.
VEGF pathway activation promotes tumor angiogenesis and
progression in a variety of human cancers, and elevated VEGF
expression correlates with poor prognosis in certain tumor types
[40–42]. However, until our report, the prognostic impact of
Figure 6. Genes contained within low copy CNAs are expressed in primary human rhabdomyosaroma but not normal fetal muscle.
Immunohistochemistry of human primary RMS and fetal muscle tissue samples. Hematoxylin and Eosin stained sections (A–C). Expression of HOXC6,
CCND2, PLXNA1 and VEGFA in embryonal rhabdomyosaroma (D, G, J, M), alveolar rhabdomyosaroma (E, H, K, N) and fetal muscle (F, I, L, O). Magnified
views of staining are shown in insets. In fetal muscle, PLXNA1 and VEGFA are only expressed in the vasculature (examples indicated by arrowheads in
L and O and corresponding insets). The cumulative frequency of positive staining within tumor subtype is shown in the top right corner of each panel
(pediatric and adult samples combined). Scale bar (panel A) = 50 mm.
doi:10.1371/journal.pgen.1003727.g006
Novel Oncogenic Events in Rhabdomyosarcoma
PLOS Genetics | www.plosgenetics.org 10 August 2013 | Volume 9 | Issue 8 | e1003727
VEGFA expression in human ERMS had not been described.
Here, we show that VEGFA is amplified as a low-copy gain in a
small cohort of zebrafish and human RMS and yet highly
expressed in a majority of human patient samples. High VEGFA
mRNA expression correlated with poor clinical outcome in human
ERMS, underscoring the importance of this pathway in driving
continued tumor growth. As VEGFA expression level is not linked
to clinical stage, it represents an important independent prognostic
indicator and a potential biomarker for therapy stratification.
Chemical inhibition of VEGF signaling in our pre-clinical in vivo
model effectively suppressed tumor growth by reducing angiogen-
esis, consistent with the findings from a pre-clinical testing of
VEGFR inhibitors on a small number of human RMS xenografts
into mice [43]. Although clinical trials of VEGF inhibitors in other
types of cancers have exhibited mixed results [44–46], our data
suggest that targeting the VEGF pathway may be a promising
therapeutic option to curb tumor growth in a subset of high-risk
ERMS patients.
In summary, our array CGH studies of zebrafish cancer have
identified conserved CNA gains with functional significance in
human ERMS. As proof of principle, we have also demonstrat-
ed the utility of zebrafish array CGH studies to identify
oncogenes that are essential for continued tumor growth in
both zebrafish and human ERMS. Our work also provides 13
additional CNA gains that are conserved in zebrafish and
human ERMS for which an essential genetic lesion has yet to be
identified – providing potential genes to interrogate in the
future. Our studies suggest that most amplified CNAs will
contain genes that regulate important processes in cancer
maintenance and growth. Moreover, our study reveals a
number of tractable features of zebrafish cancer genomes such
as small-size CNAs containing few genes within each region of
chromosomal aberration, thereby positioning the zebrafish as an
effective model system for discovering novel genes required for
continued tumor growth and maintenance within a wide
diversity of cancer types.
Methods
Animal and human protocol approval
Studies were approved by the Massachusetts General Hospital
Subcommittee on Research Animal Care under protocol
#2011N000127 (zebrafish) and by the Partners Human Research
Committee under IRB protocol #2009-P-002756 (human).
Array comparative hybridization
TuAB-strain zebrafish were co-injected at the one-cell stage
with linearized rag2-KRASG12D and rag2-dsRED DNA con-
structs as previously described [4,47]. dsRED-labeled ERMS
and adjacent non-neoplastic tissues were dissected from tumor-
bearing animals at 30–40 days of life. RNA and DNA were
extracted by Trizol (Sigma). Tumor DNA was labeled with Cy5
(Bioprime system, Invitrogen, Carlsbad, CA) and hybridized
against the matched normal samples labeled with Cy3 onto the
custom SurePrint G3 400k CGH microarray (Agilent Technol-
ogies, Santa Clara, CA). Array image scans were extracted using
Agilent Feature Extraction software (Agilent Technologies, Inc,
Santa Clara, CA), normalized for signal intensity, and imported
into the Nexus Copy Number software program version 5.1
(Biodiscovery, Inc., El Segundo, CA). CNA calls were generated
based on log2 ratio output files using a rank segmentation
algorithm. Settings were optimized using self-self hybridizations
Figure 7. Elevated VEGFA expression correlates with poor clinical outcome in rhabdomyosarcoma. Kaplan-Meier analysis was completed
using microarray gene expression data for which patient outcome is available. Comparison was made in all RMS patients, ERMS patients only, and
translocation-positive ARMS patients only. (A) HOXC6. (B) VEGFA.
doi:10.1371/journal.pgen.1003727.g007
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to reduce false positive calls. The parameters include signifi-
cance threshold 1.0 E-5, maximum continuous probe spacing of
200 kb, minimum number of probes per sequence of 3, and log2
ratios of 1.0, 0.25, 20.25 and 21.0 for high-level amplifications,
gains, losses and deletions, respectively. CNAs of interest were
determined using the aggregate function in Nexus. Aggregates
are represented as segmented regions of gain or loss shared by a
set of samples with the number of samples sharing the event
referred to as the aberration frequency. The minimum
aberration frequency required for analysis in our study was set
at $15% (n$3 of 20 zebrafish ERMS contained a common
region of gene amplification).
For the human ERMS sample analysis, normalized log2
intensity files (series number GSE27392) were downloaded from
Gene Expression Omnibus (GEO) at the National Center for
Biotechnology Information (NCBI) and imported into and
analyzed using Nexus Copy Number software (version 5.1,
BioDiscovery). This program analyzes log2 ratio output files using
a rank segmentation algorithm similar to circular binary segmen-
tation. Samples were segmented following the removal of the
greatest 3% of outliers and a minimum five-probe requirement at
a significance threshold of 1E-08. Gains and losses were defined as
regions exhibiting log2 values of 0.2 and 20.18, respectively, with
high-level amplifications and deletions defined as log2 values
greater than 0.5 and less than20.5. Following the identification of
human ERMS aberrations, homologous human regions of
zebrafish ERMS CNAs were analyzed to determine whether
common low-level amplifications were present in both zebrafish
and human ERMS samples.
Immunohistochemistry
Paraffinized human primary rhabdomyosaroma (5 ERMS
and 3 ARMS), US Biomax tissue microarray (14 ERMS and 4
ARMS, Rockville, MD), and a Children’s Oncology Group
tissue microarray were analyzed by immunohistochemical
staining as previously described [48]. HOXC6 (Sigma, 1:200),
CCND2 (Ab-Cam, 1:100), PLXNA1 (Ab-Cam; 1:200) and
VEGFA (Ab-Cam; 1:125). BGAR- biotinylated goat anti-rabbit
(Vector #BA-1000) was used as the secondary antibody.
Pathology review was completed independently by E.C. and
G.P.N.
Cell lines, siRNA transfection, stable shRNA knockdown
and Western analysis
The human RD cell line was obtained from ATCC cell
biology collection (Manassas, Virginia) and the SMS-CTR cell
line provided by Dr. Corrine Linardic (Duke University, North
Carolina). Cells were seeded at a density of 56102 cells in 6-well
plates in 2 ml of antibiotic-free 10% FBS/DMEM. 50 pg of
gene-specific smart-pool or control siRNA were transfected into
cells using RNAiMax lipofectamine transfection reagent (In-
vitrogen). For stable knockdowns, scrambled and gene-specific
shRNAs in pLKO.1-based lentiviral vectors were packaged in
293T cells. shRNAs were obtained from molecular profiling
laboratory at the Cancer Center of Massachusetts General
Hospital (Table S4). RD cells were infected with viral particles
for 24 hours at 37 degrees with polybrene (Millipore) at 4 mg/
mL and then selected with puromycin (In Vivo Gene) at 10 mg/
mL in 10%FBS/DMEM for 15 days to obtain stable lines. Total
cell lysates from knockdown experiments were immunoblotted
using primary antibodies against HOXC6 (1:500), CCND2
(1:1000), PLXNA1 (1:1000) and VEGFA (1:1000). All Western
analysis was completed three times per experiment and average
percent knockdown is noted. Incubation with HRP-conjugated
secondary antibody (1:2000) was performed in 5% milk/TBST
for 2 hours.
Cell proliferation and apoptosis assays
siRNA transfected cells were assessed by Cell Titer Glo assay as
per the manufacturer’s instructions (Promega). Cells were also
pulsed with EDU for 2 hours, harvested at 48 hours post-
transfection and processed using the EDU ClickIt Flow Cytometry
Assay kit (Alexa Fluor 647 dye, Invitrogen). Unstained cells were
used as the negative sample to facilitate gating in flow cytometry.
To assess apoptosis, cells were harvested at 48 hours post-
transfection and labeled with PE Annexin V and 7-AAD using
the PE Annexin V Apoptosis Detection Kit (BD Pharmagin).
Unstained cells, cells treated with PE Annexin V only and 7-AAD
only were used to set up gates for flow cytometry. Each analysis
was performed in triplicate. A student’s T-test was performed to
assess whether the difference in the percentage of Annexin V-
positive cells between test samples and control siRNA-transfected
cells was significant.
Cell migration assays
A wound-healing assay was performed in cells transiently
transfected with siRNA and/or cells that stably express a gene-
specific shRNA. Cell were seeded into 6-well plates and grown to
nearly confluent density. A scrape was made in each well using a
pipette tip, and cell migration across the gap was assessed after
22 hours. Images were taken at 0 and 22 hrs to calculate the
percentage of gap closure. ERMS cells were also analyzed for
altered migration in a transwell assay. Specifically, 26104 cells
were seeded in 6.5 mm-membrane inserts (Corning) in DMEM
and were allowed to migrate through the permeable membranes
(8.0 mM pore size) toward the bottom chamber containing
medium with 10% FBS. Cells were then fixed with 4%
paraformaldehyde after 24 hours and stained with hematoxylin
for 30 minutes. Unmigrated cells from the inserts were removed.
Six random fields of the migrated cells on the membranes were
imaged using the Olympus light microscope (Model MVX10,
4006 magnification) and manually counted. A Student’s T-test
was performed to assess differences between the control and
experimental groups.
Soft-agar colony formation assay
A base layer of 1% agar in 10% FBS/DMEM was prepared
in 6-well plates. Cells were resuspended in 0.5% low-melting
point agarose/10%FBS/DMEM and overlaid on the base layer
with 2.56103 cells per well and subsequently kept in the
humidified incubator with 5% CO2 with media change every 3
days for 15 days. Cells were fixed with 4% paraformaldehyde
and stained with 0.05% crystal violet. Colony formation assay
for each shRNA stable knockdown line was performed in
triplicate. Image for each well containing soft agar colonies was
taken at low magnification by light microscopy. Colony count
was performed using the ImageJ software and differences
assessed by Student T-test.
Chemical treatment of zebrafish with ERMS
Six-week old CG1 syngeneic fish were transplanted with 36104
unsorted tumor cells arising from dsRED-positive ERMS from
CG1 strain fish (Mizgireuv and Revskoy 2006; Smith et al., 2010).
Engrafted animals were treated at 6-days post-transplantation with
100 nM of cediranib (Selleck) and vehicle control (DMSO) for 7
days (including 2 24-hr drug holidays). Tumor volume was
assessed by imaging animals pre-treatment and post-treatment.
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Tumor volume was calculated by multiplying tumor area by
fluorescent intensity using image J. A Student’s T-test was
performed to assess differences between tumor size in the control
and experimental groups.
Estimating microvessel density
Six-week old fli1-GFP fish were irradiated at 25 Gy and
transplanted with 36104 unsorted ERMS cells from fish with
dsRED-positive ERMS. Fish with engrafted tumors were treated
with cediranib as described above. At the end of treatment period,
tumor tissues were isolated, fixed in 4% paraformaldehyde for
30 minutes and snap frozen. 5 mM Frozen sections were mounted
in DAPI-containing Vectashield (Invitrogen). GFP and dsRED
images were obtained at 2006 magnification using a Nikon
confocal microscope. Microvessel density was quantified using
Weidner et al. criteria [49] and differences assessed by Student T-
test.
Kaplan-Meier analysis
Kaplan-Meier analysis was completed using R with the survival
package. Median expression level for each gene was used to group
samples into high and low expression. Chi-squared tests were used
to assess overall survival differences between groups. Statistical
significance was defined as a p-value less than 0.05.
Supporting Information
Figure S1 Validation of copy number changes within CNAs
identified by array CGH in zebrafish ERMS. A. Quantitative
PCR was performed on genomic DNA extracted from represen-
tative tumor/matched normal tissues. Each tumor sample was
normalized to matched normal tissue. Each error bar indicates
standard deviation from triplicate experiments. B. Corresponding
array CGH analysis showing CNA calls based on a log2 scale.
(PDF)
Figure S2 BRAF is the only gene within this CNA interval that is
upregulated in human ERMS compared to normal muscle. Wisker
plots showing relative mRNA expression levels of BRAF (A), CRY1
(B) and TTNT1 (C) in human ERMS and ARMS with PAX3-
FKHR fusion and PAX7-FKHR fusion in comparison with juvenile
muscle as assessed by microarray gene expression.
(PDF)
Figure S3 Knockdown of candidate genes and inhibition of
VEGFA activity in ERMS cell lines. (A) ELISA to assess VEGFA
protein level in growth media of transfected cells. (B) qRT-PCR to
assess knockdown of mRNA levels of candidate genes. (Error bars
indicate standard deviation of each triplicate within each
experiment). Asterisks denote significant differences with
p,0.003 and p,0.008, respectively within each comparison.
(PDF)
Figure S4 Knockdown of CCND2, HOXC6 and PLXNA1
results in reduced growth of human SMS-CTR and RD cell lines.
(A) Western analysis of CCND2, HOXC6 and PLXNA1
knockdowns in SMS-CTR cell line using smart-pool (sp) and
two individual gene-specific siRNAs. Bottom row: GAPDH.
Percentage knockdown for each siRNA is as follows: CCND2
siRNA-sp, 98%; CCND2 siRNA#1, 57%; CCND2 siRNA#2,
91%; HOXC6 siRNA-sp, 82%; HOXC6 siRNA#1, 88%; HOXC6
siRNA#2, 75%; PLXNA1 siRNA-sp, 77%; PLXNA1 siRNA#1,
94%; PLXNA1 siRNA#2, 54%; VEGFA siRNA, 97%. (B)
Summary of cell-titer glo analysis in SMS-CTR cell line. OD
fold changes over 3 days for smart pool (sp) and individual siRNAs
are shown. Asterisk indicates statistical significance in comparison
to control siRNA treatment by Student’s t-test (p,0.05). Cell-titer
glo assay showing OD change in 3 days for RD (C–E) and SMS-
CTR (F–H) cells transfected with two individual gene-specific
siRNAs. Each error bar indicates standard deviation of triplicate
experiments.
(PDF)
Figure S5 Knockdown of CCND2, HOXC6, PLXNA1 and
VEGFA did not affect apoptosis. Annexin V analysis was
performed on RD and SMS-CTR cells transfected with siRNA
targeted against CCND2, HOXC6, PLXNA1 and VEGFA. Each
error bar indicates standard deviation of triplicate experiments.
(PDF)
Figure S6 Knockdown of PLXNA1 results in impaired
migration in a wound-healing assay. Cells transfected with siRNA
or shRNA were allowed to migrate over a scratch wound over
22 hours. Representative images of cells with control siRNA, two
gene-specific PLXNA1 siRNAs, control shRNA and two gene-
specific shRNAs at 0 hr (A–F) and 22 hrs (G–L) are shown. Scale
bar indicates 50 mm. (M) Summary of assessing PLXNA1
knockdown in wound healing assays using two gene-specific
siRNAs in RD and SMS-CTR cell lines. Eight random
measurements at each time point were made for each siRNA.
The ratio of wound closure was determined by the difference in
distance migrated over total distance. Each error bar denotes
standard deviation. (N) Summary of wound healing assays using
two gene-specific PLXNA1 shRNAs.
(PDF)
Figure S7 HoxC6 is differentially expressed in ERMS when
compared to ARMS and normal muscle. Wisker plot showing
relative mRNA expression levels of HOXC6 in human RMS in
comparison with juvenile and adult muscle as assessed by
microarray gene expression. Asterisk denotes statistical significance
based on Student’s t-test (p,0.001). PAX3-FKHR+ ARMS (P3+
ARMS), PAX7-FKHR+ ARMS (P7+ ARMS).
(PDF)
Figure S8 Kaplan-Meier analysis correlating expression levels of
CCND2 and PLXNA1 with clinical survival. Kaplan-Meier analysis
was completed using microarray data from Davicioni et al (2010)
to correlate expression levels of CCND2 and PLXNA1 with clinical
survival. Comparison was made in all RMS patients, ERMS
patients only, ARMS patients only and non-RMS patients. (A)
CCND2. (B) PLXNA1.
(PDF)
Figure S9 VEGFA transcript expression does not correlate with
clinical stage of ERMS. Kaplan-Meier analysis was completed
using microarray data from Davicioni et al (2010). (A) Stage 1. (B)
Stage 2. (C) Stage 3. (D) Stage 4. Normalized mRNA expression
levels of VEGFA across all RMS (E), ERMS (F) and ARMS (G)
samples were also assessed in box plots.
(PDF)
Table S1 Summary of zebrafish samples with recurrent regional
gains and deletions in array CGH analysis.
(PDF)
Table S2 Summary of clinical information and immunohisto-
chemical staining results of human RMS samples.
(PDF)
Table S3 Summary of clinical information and immunohisto-
chemical staining results of RMS samples in the Children’s
Oncology Group tissue microarray.
(PDF)
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Table S4 Summary of shRNA sequences and quantitative
primers used in array CGH validation studies.
(PDF)
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